Chung Matthew J, Novak Eric, Brown David L
Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri, USA.
Coron Artery Dis. 2017 Jun;28(4):301-306. doi: 10.1097/MCA.0000000000000492.
Survivors of a myocardial infarction (MI) are at a considerable risk of developing further cardiovascular events, including recurrent MI, heart failure, stroke, and death. Patients with type 2 diabetes mellitus and stable ischemic heart disease (SIHD) have worse outcomes than their nondiabetic counterparts, and those with previous MI may be at particularly high risk. Yet, little is known about the effect of adding prompt revascularization to intensive medical therapy in this high-risk group.
We carried out a post-hoc analysis of the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, which randomized patients with type 2 diabetes mellitus and SIHD to prompt revascularization with percutaneous coronary intervention or coronary artery bypass grafting in addition to intensive medical therapy or intensive medical therapy alone. Previous MI status was defined by a history of MI or pathologic Q-waves. The primary endpoints were death, nonfatal or fatal MI, nonfatal or fatal stroke, congestive heart failure, and a composite of death/MI/stroke.
Of the 2280 patients with evaluable data, 936 had previous MI. In these patients, there were no differences in the 5-year event-free rates of all-cause death, MI, stroke, congestive heart failure, or death/MI/stroke between those who were randomized to prompt revascularization in addition to intensive medical therapy and those who were randomized to intensive medical therapy alone.
In diabetic patients with SIHD and previous MI, adding prompt revascularization to intensive medical therapy yielded no benefit compared with intensive medical therapy alone. These findings underscore the importance of intensive medical therapy in mitigating further ischemic events.
心肌梗死(MI)幸存者发生进一步心血管事件的风险相当高,包括复发性心肌梗死、心力衰竭、中风和死亡。2型糖尿病和稳定型缺血性心脏病(SIHD)患者的预后比非糖尿病患者更差,而既往有心肌梗死的患者可能风险特别高。然而,对于在这一高危人群中强化药物治疗基础上增加及时血运重建的效果知之甚少。
我们对“旁路血管成形血运重建研究2糖尿病”试验进行了事后分析,该试验将2型糖尿病和SIHD患者随机分为强化药物治疗基础上接受经皮冠状动脉介入治疗或冠状动脉旁路移植术的及时血运重建组,或仅接受强化药物治疗组。既往心肌梗死状态根据心肌梗死病史或病理性Q波定义。主要终点为死亡、非致命性或致命性心肌梗死、非致命性或致命性中风、充血性心力衰竭以及死亡/心肌梗死/中风的复合终点。
在2280例有可评估数据的患者中,936例有既往心肌梗死病史。在这些患者中,随机分配至强化药物治疗基础上接受及时血运重建组和仅接受强化药物治疗组的患者,在全因死亡、心肌梗死、中风、充血性心力衰竭或死亡/心肌梗死/中风的5年无事件发生率方面没有差异。
在患有SIHD且有既往心肌梗死病史的糖尿病患者中,强化药物治疗基础上增加及时血运重建与单纯强化药物治疗相比没有益处。这些发现强调了强化药物治疗在减轻进一步缺血事件方面的重要性。